Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis

ABSTRACT: Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis

PROVIDER: PRJNA1221860 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32296300.fastq.gz	Fastqsanger.gz
	SRR32296301.fastq.gz	Fastqsanger.gz
	SRR32296302.fastq.gz	Fastqsanger.gz
	SRR32296303.fastq.gz	Fastqsanger.gz
	SRR32296304.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 107

Similar Datasets

Single-cell eQTL analysis identifies genetic variation underlying metabolic dysfunction-associated steatohepatitis

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized for its medical and socioeconomic impacts, driven by diverse genetic and environmental factors. To address the urgent need for individually tailored therapies, we performed single-cell expression quantitative trait loci (sc-eQTL) analysis on liver biopsies from 25 MASLD patients and 23 controls. This approach identified over 3,500 sc-eQTLs across major liver cell types and cell state-interacting eQTLs (ieQTLs) with significant enrichment for disease heritability (for MASLD trait, ieQTL enrichment odds ratio = 10.27). We integrated transcription factors (TFs) as upstream regulators of ieQTLs, revealing 601 functional units (“quartets”) composed of TFs, cell states, ieSNPs, and ieGenes. From these results, we pinpoint the loss of an eQTL in EFHD1 during hepatocyte maladaptation associated with genotype-specific regulation by FOXO1, further contributing to the risk of MASLD. Our approach underscores the role of eQTL analysis in capturing crucial genetic variations that influence gene expression and clinical outcomes in complex diseases.

2025-02-12 | GSE289173 | GEO

Pneumosepsis survival in the setting of obesity leads to persistent steatohepatitis and metabolic dysfunction.

Project description:Pneumosepsis survival in the setting of obesity leads to persistent steatohepatitis and metabolic dysfunction.

2023-05-02 | GSE231504 | GEO

Potential utility of L-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis

Project description:We examined the potential utility of L-carnitine for alleviating metabolic dysfunction-associated steatohepatitis (MASH) and preventing the development of hepatocellular carcinoma. Short-term L-carnitine administration ameliorated MASH through its anti-inflammatory effects.

2024-04-24 | GSE261938 | GEO

Hepatoprotective effect of cinnabarinic acid in metabolic dysfunction-associated steatohepatitis

Project description:Hepatoprotective effect of cinnabarinic acid in metabolic dysfunction-associated steatohepatitis

| PRJNA1162523 | ENA

Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis

Project description:We explore whether a low-energy diet intervention for Metabolic dysfunction-associated steatohepatitis (MASH) improves liver disease by means of modulating the gut microbiome. 16 individuals were given a low-energy diet (880 kcal, consisting of bars, soups, and shakes) for 12 weeks, followed by a stepped re-introduction to whole for an additional 12 weeks. Stool samples were obtained at 0, 12, and 24 weeks for microbiome analysis. Fecal microbiome were measured using 16S rRNA gene sequencing. Positive control (Zymo DNA standard D6305) and negative control (PBS extraction) were included in the sequencing. We found that low-energy diet improved MASH disease without lasting alterations to the gut microbiome.

2024-12-31 | E-MTAB-14061 | biostudies-arrayexpress

Chitinase 1: A novel therapeutic target in metabolic dysfunction-associated steatohepatitis

Project description:Chitinase 1: A novel therapeutic target in metabolic dysfunction-associated steatohepatitis

| PRJNA1124123 | ENA

Hepatoprotective effect of cinnabarinic acid in metabolic dysfunction-associated steatohepatitis

Project description:Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by accumulation of fats in liver, chronic inflammation, hepatocytic ballooning, and fibrosis. This study investigates role of endogenous Aryl hydrocarbon Receptor (AhR) agonist, cinnabarinic acid (CA) in protection against in vivo mouse model of MASH. To analyze the transcriptomic changes in response to CA treatment, male AhRfl/fl (AhR-floxed) mice were subjected to control diet (CD), high-fat high-fructose high-cholesterol diet (MASH diet, MD), and fed with MASH diet and treated with CA thrice a week for 20-week period. RNA sequencing revealed altered expression of multiple genes involved in fatty acid metabolism and inflammation in response to CA treatment. Gene set enrichment analysis indicated enrichment of AMPK among other kinases. Subsequent immunoblotting and immunofluorescence studies performed on CA-treated livers and primary hepatocytes confirmed activated AMPK signaling. Moreover, in a hepatocyte-specific AhR knockout mice livers (AhR-hKO, constructed by crossing AhRfl/fl with alb-Cre), CA failed to phosphorylate AMPK strongly indicating that CA-induced AMPK mediated protection against lipotoxicity in MASH is dependent on hepatic AhR signaling.

2025-07-23 | GSE277498 | GEO

Lower H2S-generating enzyme levels and persulfidation-mediated protein protection characterize metabolic dysfunction-associated steatohepatitis

Project description:Metabolic dysfunction–associated steatohepatitis (MASH), marked by hepatic steatosis and inflammation, is a major risk for cirrhosis and liver cancer. Obesity-induced oxidative stress plays a central role in MASH promoting protein damage and dysfunction. Cysteine persulfidation (PSSH), a post-translational modification regulated by hydrogen sulfide (H2S), is involved in protein stability and cellular protection. However, the role of PSSH in MASH is poorly understood. We found that H2S-producing enzymes are downregulated in livers with fibrosis and inflammation, leading to decreased hepatic PSSH. Using dimedone-switch-based mass spectrometry, we mapped the alterations in the liver persulfidome during diet-induced fibrosis and inflammation. While the levels of H2S-producing enzymes dropped, some proteins, including protein tyrosine phosphatases (PTPs) and redox regulators, showed increased PSSH. This change suggests that H2S-mediated persulfidation helps protect proteins from oxidative damage. Overall, decreased H2S enzyme expression and reduced PSSH may impair protection against oxidative stress, contributing to liver dysfunction in obesity.

2025-08-04 | PXD057932 | Pride

Genetic and pharmacological targeting of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis

Project description:Genetic and pharmacological targeting of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis

| PRJNA1105091 | ENA

Establishment and Characterization of Mouse Metabolic dysfunction-associated steatohepatitis-related Hepatocellular carcinoma organoids

Project description:Establishment and Characterization of Mouse Metabolic dysfunction-associated steatohepatitis-related Hepatocellular carcinoma organoids

| PRJNA1134666 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data